Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Authors: David J. Straus, Monika Długosz‐Danecka, Joseph M. Connors, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech‐Marańda, Tatyana Feldman, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Jan Walewski, Radhakrishnan Ramchandren, Pier Luigi Zinzani, Martin Hutchings, Javier Muñoz, Hun Ju Lee, Won Seog Kim, Ranjana H. Advani, Stephen M. Ansell, Anas Younes, Andrea Gallamini, Rachael Liu, Meredith Little, Keenan Fenton, Michelle A. Fanale, John Radford - The Lancet 2021 cited by 160